Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 178
8
Diseases
33
Unique genes
0.210
Avg. similarity score
Agammaglobulinemia
Most-connected disease (6 links)
Disease
Searched: autosomal agammaglobulinemia
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
autosomal agammaglobulinemia
Agammaglobulinemia
Activated pi3k-delta syndrome
Combined immunodeficiency with facio-oculo-skeletal anomalies
immunodeficiency 14
immunodeficiency 14b, autosomal recessive
Roifman syndrome
Burkitt lymphoma
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Agammaglobulinemia | 6 | 6 | 13 |
| Activated pi3k-delta syndrome | 5 | 5 | 3 |
| Combined immunodeficiency with facio-oculo-skeletal anomalies | 5 | 5 | 2 |
| immunodeficiency 14 | 5 | 5 | 1 |
| immunodeficiency 14b, autosomal recessive | 5 | 5 | 1 |
| Roifman syndrome | 4 | 4 | 3 |
| Burkitt lymphoma | 2 | 2 | 19 |
| autosomal agammaglobulinemia | 2 | 2 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| PIK3CD | 6 / 8 | Activated pi3k-delta syndrome, Agammaglobulinemia, Combined immunodeficiency with facio-oculo-skeletal anomalies, immunodeficiency 14 and 2 more |
| PIK3R1 | 3 / 8 | Activated pi3k-delta syndrome, Agammaglobulinemia, Burkitt lymphoma |
| TCF3 | 3 / 8 | Agammaglobulinemia, autosomal agammaglobulinemia, Burkitt lymphoma |
| KNSTRN | 2 / 8 | Combined immunodeficiency with facio-oculo-skeletal anomalies, Roifman syndrome |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | Reactome | 5 / 23 | 79.1× | 3.71e-9 | 3.46e-7 ✓ sig. |
| Acute myeloid leukemia | KEGG | 5 / 68 | 26.8× | 1.05e-6 | 4.89e-5 ✓ sig. |
| Central carbon metabolism in cancer | KEGG | 5 / 71 | 25.6× | 1.31e-6 | 5.92e-5 ✓ sig. |
| Human T-cell leukemia virus 1 infection | KEGG | 7 / 224 | 11.4× | 2.02e-6 | 8.52e-5 ✓ sig. |
| B cell receptor signaling pathway | KEGG | 5 / 91 | 20.0× | 4.49e-6 | 1.69e-4 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 6 / 170 | 12.8× | 5.94e-6 | 2.11e-4 ✓ sig. |
| Pathways in cancer | KEGG | 9 / 533 | 6.1× | 9.26e-6 | 3.04e-4 ✓ sig. |
| Endometrial cancer | KEGG | 4 / 59 | 24.7× | 1.93e-5 | 5.68e-4 ✓ sig. |
| Signaling pathways regulating pluripotency of stem cells | KEGG | 5 / 144 | 12.6× | 4.19e-5 | 1.08e-3 ✓ sig. |
| Chronic myeloid leukemia | KEGG | 4 / 77 | 18.9× | 5.55e-5 | 1.35e-3 ✓ sig. |
| CD22 mediated BCR regulation | Reactome | 2 / 5 | 146× | 7.28e-5 | 1.68e-3 ✓ sig. |
| Colorectal cancer | KEGG | 4 / 87 | 16.7× | 8.95e-5 | 2.00e-3 ✓ sig. |
| Interleukin-7 signaling | Reactome | 3 / 33 | 33.1× | 9.75e-5 | 2.14e-3 ✓ sig. |
| Small cell lung cancer | KEGG | 4 / 93 | 15.7× | 1.16e-4 | 2.46e-3 ✓ sig. |
| Primary immunodeficiency | KEGG | 3 / 38 | 28.7× | 1.49e-4 | 3.01e-3 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| B cell differentiation | GO:0030183 | 7 / 80 | 49.5× | 7.87e-11 | 2.36e-8 ✓ sig. |
| B cell receptor signaling pathway | GO:0050853 | 4 / 56 | 40.4× | 2.77e-6 | 1.88e-4 ✓ sig. |
| negative regulation of wound healing, spreading of epidermal cells | GO:1903690 | 2 / 5 | 227× | 3.01e-5 | 1.23e-3 ✓ sig. |
| positive regulation of DNA-templated transcription | GO:0045893 | 8 / 778 | 5.8× | 4.79e-5 | 1.75e-3 ✓ sig. |
| transcription initiation-coupled chromatin remodeling | GO:0045815 | 3 / 41 | 41.4× | 5.11e-5 | 1.84e-3 ✓ sig. |
| myeloid leukocyte differentiation | GO:0002573 | 2 / 7 | 162× | 6.32e-5 | 2.15e-3 ✓ sig. |
| B cell activation | GO:0042113 | 3 / 44 | 38.6× | 6.32e-5 | 2.15e-3 ✓ sig. |
| positive regulation of myoblast differentiation | GO:0045663 | 3 / 47 | 36.1× | 7.72e-5 | 2.50e-3 ✓ sig. |
| germinal center B cell differentiation | GO:0002314 | 2 / 9 | 126× | 1.08e-4 | 3.21e-3 ✓ sig. |
| positive regulation of miRNA transcription | GO:1902895 | 3 / 56 | 30.3× | 1.30e-4 | 3.71e-3 ✓ sig. |
| regulation of G1/S transition of mitotic cell cycle | GO:2000045 | 3 / 57 | 29.8× | 1.38e-4 | 3.85e-3 ✓ sig. |
| fibroblast apoptotic process | GO:0044346 | 2 / 11 | 103× | 1.65e-4 | 4.41e-3 ✓ sig. |
| positive regulation of transcription by RNA polymerase II | GO:0045944 | 9 / 1,208 | 4.2× | 1.79e-4 | 4.67e-3 ✓ sig. |
| regulation of multicellular organismal development | GO:2000026 | 2 / 15 | 75.5× | 3.13e-4 | 6.98e-3 ✓ sig. |
| immune response | GO:0006955 | 6 / 543 | 6.3× | 3.32e-4 | 7.26e-3 ✓ sig. |